Medicare Part D 2027: A Complete Guide to Changes, Costs, and Coverage

The year 2027 marks a significant milestone in the evolution of Medicare. Following the landmark restructuring of the Inflation Reduction Act (IRA), beneficiaries will see a more stabilized but adjusted landscape for prescription drug coverage.

Whether you are approaching Medicare eligibility or reviewing your current plan, understanding the Medicare Part D 2027 updates is essential for managing your healthcare budget.


What’s New for Medicare Part D in 2027?

By 2027, the Medicare Part D benefit has moved past its transition phase and into a period of "indexed" stability. The most notable changes involve the expansion of drug price negotiations and adjustments to out-of-pocket limits.

1. Expanded Drug Price Negotiations

For the first time, Medicare will apply "Maximum Fair Prices" to a broader list of high-cost medications.

  • 15 Additional Drugs: Building on the 10 drugs from 2026, 15 more high-expenditure Part D drugs will have negotiated lower prices starting January 1, 2027.

  • Focus Areas: These negotiated prices typically target treatments for diabetes, heart disease, and autoimmune conditions.

2. The 2027 Benefit Design: Deductibles and Caps

While the "Donut Hole" is officially a thing of the past, the costs within the Part D structure are indexed annually.

Benefit Feature 2027 Amount
Annual Deductible $700
Out-of-Pocket Cap (RxMOOP) $2,400
Initial Coverage Coinsurance 25% (Standard)
Catastrophic Phase Cost $0

3. The $2,400 Out-of-Pocket (OOP) Threshold

One of the most critical updates for 2027 is the rise of the RxMOOP to $2,400.

  • Why the increase? After the initial $2,000 cap in 2025, the law mandates that this limit is indexed to the growth of per capita Part D spending.

  • What it means for you: Once you spend $2,400 out of your own pocket (including the deductible and copays), you pay nothing ($0) for your covered Part D drugs for the remainder of the calendar year.


Core Protections That Remain in Effect

Despite the rising deductible, 2027 maintains the patient-centered protections established in previous years:

  • $35 Insulin Cap: Your cost for a one-month supply of covered insulin will not exceed $35, even if you haven't met your $700 deductible.

  • $0 Vaccines: Recommended adult vaccines (such as Shingles, RSV, and Tetanus) remain available at zero cost-sharing.

  • M3P (Medicare Prescription Payment Plan): You retain the right to "smooth" your out-of-pocket costs into monthly installments throughout the year, preventing a massive bill at the pharmacy in January.


How to Prepare for 2027 Enrollment

The Annual Election Period (AEP)—running from October 15 to December 7, 2026—is your window to secure your 2027 coverage.

  1. Check the Formulary: With new negotiated prices, many plans may change which drugs they prioritize. Ensure your specific medications are still covered.

  2. Compare Premiums: CMS limits the growth of base premiums to 6% annually, but individual plan premiums can still fluctuate.

  3. Review the "Plan Finder": Use the official Medicare.gov tool to see how the $700 deductible and $2,400 cap will affect your total annual spend.

The 2027 Negotiated Drug List

Drug Name Manufacturer Primary Condition Treated
Ozempic / Rybelsus / Wegovy Novo Nordisk Diabetes / Cardiovascular / Obesity
Trelegy Ellipta GSK COPD / Asthma
Xtandi Astellas / Pfizer Prostate Cancer
Pomalyst Bristol Myers Squibb Multiple Myeloma
Ibrance Pfizer Breast Cancer
Ofev Boehringer Ingelheim Pulmonary Fibrosis
Linzess AbbVie IBS-C / Chronic Constipation
Calquence AstraZeneca Blood Cancers (CLL/SLL)
Austedo / Austedo XR Teva Tardive Dyskinesia / Huntington’s
Breo Ellipta GSK Asthma / COPD
Tradjenta Boehringer Ingelheim Type 2 Diabetes
Xifaxan Bausch / Salix IBS-D / Liver Disease
Vraylar AbbVie Bipolar / Depression / Schizophrenia
Janumet / Janumet XR Merck Type 2 Diabetes
Otezla Amgen Psoriasis / Psoriatic Arthritis
Medicare Part D 2027

Local phone/text:

913-232-2006